Research programme: histone deacetylase-6 inhibitors - Eikonizo Therapeutics
Latest Information Update: 12 Apr 2023
At a glance
- Originator Eikonizo Therapeutics
- Developer Eikonizo Therapeutics; The McQuade Center for Strategic Research and Development
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- Research Autosomal dominant polycystic kidney disease; Cardiovascular disorders; Peripheral nervous system diseases
Most Recent Events
- 12 Apr 2023 Early research in Autosomal dominant polycystic kidney disease in USA (unspecified route) (Eikonizo Therapeutics pipeline, April 2023)
- 12 Apr 2023 Early research in Cardiovascular disorders in USA (unspecified route) (Eikonizo Therapeutics pipeline, April 2023)
- 12 Apr 2023 Early research in Peripheral nervous system diseases in USA (unspecified route) (Eikonizo Therapeutics pipeline, April 2023)